What drives today's volume spike in BAYN.DE stock?

Volume rose after Bayer proposed a glyphosate settlement (~USD 7.25B) and media reports highlighted legal progress; traders reacted ahead of the 2026-03-04 earnings date, increasing activity on XETRA.

Is BAYN.DE stock cheap based on valuation metrics?

Valuation shows Price/Book **1.53** and Price/Sales **0.98**, suggesting value, but negative EPS and high net debt (netDebt/EBITDA **5.53**) mean the cheap multiple carries risk until litigation clears.

What price targets should investors watch for BAYN.DE stock?

Meyka AI model projects **monthly EUR 49.38** and **quarterly EUR 59.96**. Practical targets in our analysis are conservative **EUR 43.00**, base **EUR 50.00**, and bullish **EUR 62.00**, depending on legal outcomes and earnings.

How does the sector affect BAYN.DE stock outlook?

Healthcare peers trade at higher average PE; Bayer's Crop Science exposure adds cyclicality. Sector trends and Pharma product launches will influence BAYN.DE's recovery and relative performance.

DE Stocks

BAYN.DE Bayer XETRA pre-market 20 Feb 2026 EUR 45.58: settlement news lifts activity

ByHuzaifa Zahoor February 20, 2026

BAYN.DE stock opened pre-market at EUR 45.58 on 20 Feb 2026 after Bayer’s proposed glyphosate settlement drew heavy trading and a spike in volume. The stock shows volume 3,957,644 versus an average of 3,529,614, and intraday range EUR 45.11–46.33. Investors are weighing litigation cash outflows against steady cash generation from Pharmaceuticals and Crop Science, making BAYN.DE stock a top pick in today’s most active list on XETRA.